NCT02221258View on ClinicalTrials.gov

Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA)

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

FURESTEM-RA Inj.

Patients will be treated FURESTEM-RA Inj.+DMARDs(Disease-Modifying antirheumatic drugs)

Trial Locations (1)

156-707

Seoul national University Boramae medical center, Seoul

All Listed Sponsors
lead

Kang Stem Biotech Co., Ltd.

INDUSTRY

NCT02221258 - Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA) | Biotech Hunter | Biotech Hunter